{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:56:56Z","timestamp":1793422616525,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001320","name":"Roswell Park Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.diabres.2023.110776","type":"journal-article","created":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T12:33:38Z","timestamp":1686486818000},"page":"110776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy \u2013 A comprehensive cancer center experience"],"prefix":"10.1016","volume":"202","author":[{"given":"Zhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-7153","authenticated-orcid":false,"given":"Rajeev","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Riebandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110776_b0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156800961506150805145120","article-title":"Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety","volume":"15","author":"Azoury","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.diabres.2023.110776_b0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.diabres.2023.110776_b0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/ijmr.IJMR_313_19","article-title":"The side effects of immune checkpoint inhibitor therapy on the endocrine system","volume":"154","author":"Goyal","year":"2021","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.diabres.2023.110776_b0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.diabres.2023.110776_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.diabres.2023.110776_b0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.diabres.2023.110776_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108115","article-title":"Immune checkpoints inhibitors and hyperglycemia: a meta-analysis of randomized controlled trials","volume":"162","author":"Monami","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2023.110776_b0040","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2023.110776_b0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.diabres.2023.110776_b0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.diabres.2023.110776_b0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabres.2023.110776_b0060","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2023.110776_b0065","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.diabres.2023.110776_b0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.diabres.2023.110776_b0075","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes","volume":"46","author":"American Diabetes Association","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110776_b0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2012.12.026","article-title":"The long and winding road to optimal HbA1c measurement","volume":"418","author":"Little","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.diabres.2023.110776_b0085","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db07-1260","article-title":"Protective role of programmed death 1 Ligand 1 (PD-L1) in nonobese diabetic mice","volume":"57","author":"Wang","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2023.110776_b0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.diabres.2023.110776_b0095","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.diabres.2023.110776_b0100","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor-associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110776_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabres.2023.110776_b0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.metabol.2017.09.013","article-title":"Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes","volume":"78","author":"Gallo","year":"2018","journal-title":"Metabolism"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:26:04Z","timestamp":1759173964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723005399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":22,"alternative-id":["S0168822723005399"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110776","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy \u2013 A comprehensive cancer center experience","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110776"}}